TrialNature medicine2026

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.

Grace Lai-Hung Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.